ORIGIO a/s, a listed medtech company on the Oslo
Stock Exchange (OSE: ORO) today announces preliminary
results for the period January 1 - March 31, 2011, as
an update on the performance in the current financial
year. The final financial report for the first
quarter, 2011, will be released on April 28, 2011.
·Reported revenue up by 26% to DKK 92.4 million for
the quarter
·Organic growth of 24% in constant currency
·EBITDA before special items up by 21% to DKK 16.2
million, generating a EBITDA-margin before special
items of 18%
·EBIT amounted to DKK 11.6 million equal to an EBIT-
margin of 13%
·Net profit before tax of DKK 8.0 million and Net
profit of DKK 4.6 million
·Operating cash flow of DKK 0.8 million, compared to
DKK -3.3 million in Q1 2010
The financial outlook for 2011 is unchanged and will
be reassessed in connection with the Q2 report, 2011,
at the latest.
ORIGIO expects to publish its final Q1 report for the
period January 1 - March 31, 2011, on April 28, 2011.
Stock Exchange (OSE: ORO) today announces preliminary
results for the period January 1 - March 31, 2011, as
an update on the performance in the current financial
year. The final financial report for the first
quarter, 2011, will be released on April 28, 2011.
·Reported revenue up by 26% to DKK 92.4 million for
the quarter
·Organic growth of 24% in constant currency
·EBITDA before special items up by 21% to DKK 16.2
million, generating a EBITDA-margin before special
items of 18%
·EBIT amounted to DKK 11.6 million equal to an EBIT-
margin of 13%
·Net profit before tax of DKK 8.0 million and Net
profit of DKK 4.6 million
·Operating cash flow of DKK 0.8 million, compared to
DKK -3.3 million in Q1 2010
The financial outlook for 2011 is unchanged and will
be reassessed in connection with the Q2 report, 2011,
at the latest.
ORIGIO expects to publish its final Q1 report for the
period January 1 - March 31, 2011, on April 28, 2011.
15/4 2011 12:36 BiopOrBust 1
41329 Tilsyneladende er Origio et firma der ligefrem lytter til hvad aktionærerne har at sige, jeg bliver da mere og mere positiv på den babybiks...
Since the publication on March 29, 2011 of the agenda
for the Annual General Meeting, the Board of
Directors of ORIGIO has been in dialogue with a
number of shareholders in the company, in particular
in respect of the proposal to increase the share
capital (item 6.1 of the agenda) and the proposal to
issue warrants to the employees of the company (item
6.3 of the agenda). Based on the points of view
expressed by the shareholders during these dialogues,
the Board of Directors states as follows:
The Board of Directors has taken and will take due
notice of the preferences regarding an increase of
the companys share capital in the form of a Rights
Issue with subscription rights for the existing
shareholders
Moreover, the Board of Directors specifies that the
intention behind the suggested increase of the
companys share capital has been to ensure a fixed
amount of funding for the further profitable growth
within the in vitro fertilisation (IVF) market in
line with the information given in the notice of
March 29, 2011. Since the aim of the proposal to
increase the share capital has been to reach a level
of NOK 130 million in proceeds, proposals entailing a
limitation of the suggested proxy to an amount of
this level would not be inconsistent with the
original and continued aim of the Board of Directors.
Any utilization of a proxy granted by the
shareholders during the General Meeting mandating the
Board of Directors to increase the share capital will
be based on the Board of Directors giving further
information on the use of proceeds in accordance with
the companys growth and acquisition strategy, and
such information will be duly provided, amongst
others in the prospectus required to be prepared in
connection with increasing the share capital.
In respect of the proposal on warrants, the Board of
Directors will take this opportunity to clarify that
the proposal in respect of the element on the annual
increase of the shareprice on Oslo Børs is in line
with the proposal from the Companys shareholders as
expressed at the ordinary General Meeting in 2008.
Furthermore, it forms part of the policy adopted by
the Board of Directors that warrants cannot and thus
will not be granted to members of the Board of
Directors.
ORIGIOs Annual General Meeting will take place on
Thursday, April 28, 2011 at 12:00 - 14:00 oclock at
Felix Konferansesenter, Bryggetorget 3, 0125 Oslo,
Norway.
Url: http://www.newsweb.no/index.jsp?messageId280377
Since the publication on March 29, 2011 of the agenda
for the Annual General Meeting, the Board of
Directors of ORIGIO has been in dialogue with a
number of shareholders in the company, in particular
in respect of the proposal to increase the share
capital (item 6.1 of the agenda) and the proposal to
issue warrants to the employees of the company (item
6.3 of the agenda). Based on the points of view
expressed by the shareholders during these dialogues,
the Board of Directors states as follows:
The Board of Directors has taken and will take due
notice of the preferences regarding an increase of
the companys share capital in the form of a Rights
Issue with subscription rights for the existing
shareholders
Moreover, the Board of Directors specifies that the
intention behind the suggested increase of the
companys share capital has been to ensure a fixed
amount of funding for the further profitable growth
within the in vitro fertilisation (IVF) market in
line with the information given in the notice of
March 29, 2011. Since the aim of the proposal to
increase the share capital has been to reach a level
of NOK 130 million in proceeds, proposals entailing a
limitation of the suggested proxy to an amount of
this level would not be inconsistent with the
original and continued aim of the Board of Directors.
Any utilization of a proxy granted by the
shareholders during the General Meeting mandating the
Board of Directors to increase the share capital will
be based on the Board of Directors giving further
information on the use of proceeds in accordance with
the companys growth and acquisition strategy, and
such information will be duly provided, amongst
others in the prospectus required to be prepared in
connection with increasing the share capital.
In respect of the proposal on warrants, the Board of
Directors will take this opportunity to clarify that
the proposal in respect of the element on the annual
increase of the shareprice on Oslo Børs is in line
with the proposal from the Companys shareholders as
expressed at the ordinary General Meeting in 2008.
Furthermore, it forms part of the policy adopted by
the Board of Directors that warrants cannot and thus
will not be granted to members of the Board of
Directors.
ORIGIOs Annual General Meeting will take place on
Thursday, April 28, 2011 at 12:00 - 14:00 oclock at
Felix Konferansesenter, Bryggetorget 3, 0125 Oslo,
Norway.
Url: http://www.newsweb.no/index.jsp?messageId280377
